ReproCELL Incorporated
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder ce… Read more
ReproCELL Incorporated (6RC) - Net Assets
Latest net assets as of September 2025: €8.68 Billion EUR
Based on the latest financial reports, ReproCELL Incorporated (6RC) has net assets worth €8.68 Billion EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€9.36 Billion) and total liabilities (€688.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €8.68 Billion |
| % of Total Assets | 92.65% |
| Annual Growth Rate | 5.11% |
| 5-Year Change | 66.66% |
| 10-Year Change | 23.64% |
| Growth Volatility | 16.49 |
ReproCELL Incorporated - Net Assets Trend (2014–2025)
This chart illustrates how ReproCELL Incorporated's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ReproCELL Incorporated (2014–2025)
The table below shows the annual net assets of ReproCELL Incorporated from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €8.98 Billion | +8.10% |
| 2024-03-31 | €8.31 Billion | +9.72% |
| 2023-03-31 | €7.58 Billion | +4.47% |
| 2022-03-31 | €7.25 Billion | +34.50% |
| 2021-03-31 | €5.39 Billion | -11.01% |
| 2020-03-31 | €6.06 Billion | -14.33% |
| 2019-03-31 | €7.07 Billion | +13.17% |
| 2018-03-31 | €6.25 Billion | -15.20% |
| 2017-03-31 | €7.37 Billion | +1.40% |
| 2016-03-31 | €7.27 Billion | +2.58% |
| 2015-03-31 | €7.08 Billion | +36.39% |
| 2014-03-31 | €5.19 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ReproCELL Incorporated's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 107729400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €58.29 Million | 0.65% |
| Other Components | €8.93 Billion | 99.35% |
| Total Equity | €8.98 Billion | 100.00% |
ReproCELL Incorporated Competitors by Market Cap
The table below lists competitors of ReproCELL Incorporated ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bhiraj Office Leasehold Real Estate Investment Trust
BK:BOFFICE
|
$67.56 Million |
|
Lassila &Tikanoja Oyj
HE:LAT1V
|
$67.58 Million |
|
Pliant Therapeutics Inc
NASDAQ:PLRX
|
$67.62 Million |
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLAC
|
$67.62 Million |
|
Kernel Holding SA
F:0KE
|
$67.54 Million |
|
Anhui Xinbo Aluminum Co Ltd
SHE:003038
|
$67.51 Million |
|
Alterity Therapeutics Ltd
NASDAQ:ATHE
|
$67.51 Million |
|
Sappe Public Company Limited
BK:SAPPE
|
$67.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ReproCELL Incorporated's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,311,593,000 to 8,984,946,000, a change of 673,353,000 (8.1%).
- Net income of 103,245,000 contributed positively to equity growth.
- New share issuances of 680,110,000 increased equity.
- Other factors decreased equity by 110,002,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €103.25 Million | +1.15% |
| Share Issuances | €680.11 Million | +7.57% |
| Other Changes | €-110.00 Million | -1.22% |
| Total Change | €- | 8.10% |
Book Value vs Market Value Analysis
This analysis compares ReproCELL Incorporated's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | €120.87 | €0.72 | x |
| 2018-03-31 | €97.76 | €0.72 | x |
| 2019-03-31 | €99.48 | €0.72 | x |
| 2020-03-31 | €84.76 | €0.72 | x |
| 2021-03-31 | €75.17 | €0.72 | x |
| 2022-03-31 | €88.17 | €0.72 | x |
| 2023-03-31 | €89.01 | €0.72 | x |
| 2024-03-31 | €93.45 | €0.72 | x |
| 2025-03-31 | €94.89 | €0.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ReproCELL Incorporated utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.47%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.08x
- Recent ROE (1.15%) is above the historical average (-11.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -2.56% | -28.91% | 0.08x | 1.04x | €-652.40 Million |
| 2015 | -6.37% | -79.54% | 0.07x | 1.07x | €-1.16 Billion |
| 2016 | -26.99% | -183.96% | 0.13x | 1.10x | €-2.69 Billion |
| 2017 | -12.37% | -72.48% | 0.16x | 1.07x | €-1.65 Billion |
| 2018 | -34.76% | -234.50% | 0.14x | 1.06x | €-2.80 Billion |
| 2019 | -8.51% | -55.25% | 0.15x | 1.06x | €-1.31 Billion |
| 2020 | -16.80% | -84.72% | 0.18x | 1.08x | €-1.62 Billion |
| 2021 | -15.09% | -63.17% | 0.21x | 1.12x | €-1.35 Billion |
| 2022 | -7.93% | -25.74% | 0.28x | 1.12x | €-1.30 Billion |
| 2023 | -4.03% | -10.34% | 0.35x | 1.10x | €-1.06 Billion |
| 2024 | -0.38% | -1.29% | 0.27x | 1.09x | €-862.57 Million |
| 2025 | 1.15% | 3.47% | 0.31x | 1.08x | €-795.25 Million |
Industry Comparison
This section compares ReproCELL Incorporated's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ReproCELL Incorporated (6RC) | €8.68 Billion | -2.56% | 0.08x | $67.55 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |